Xu Chunsen, Yamamoto-Ibusuki Mutsuko, Yamamoto Yutaka, Yamamoto Satoko, Fujiwara Saori, Murakami Keiichi, Okumura Yasuhiro, Yamaguchi Lisa, Fujiki Yoshitaka, Iwase Hirotaka
Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo Kumamoto, Kumamoto, 860-8556, Japan.
Breast Cancer. 2014 Jul;21(4):482-90. doi: 10.1007/s12282-012-0403-9. Epub 2012 Sep 12.
Survivin plays a key role in the initiation and progression of breast cancer. However, its prognostic relevance to breast cancer patients has long been a matter of debate. The purpose of this study was to examine the expression of survivin and its role in predicting clinical outcome in a series of human breast cancer cases both at the mRNA and protein level.
Formalin-fixed paraffin-embedded tumor tissues from 245 female patients with invasive breast cancer and 13 patients with ductal carcinoma in situ were examined for survivin mRNA by quantitative real-time RT-PCR (RT-qPCR). In addition, 237 of these tumors with invasive breast cancer were available for immunohistochemistry (IHC). The relationship between survivin status and clinicopathological characteristics and prognosis was evaluated.
RT-qPCR revealed that high levels of survivin mRNA were strongly associated with high nuclear grade, positive axillary lymph nodes, negative hormone receptor status, positive Her2 amplification, higher Ki67 labeling index, and presence of vascular invasion. In the Cox proportional regression model analysis, survivin mRNA was shown to be a significant univariate parameter for relapse-free survival (RFS), distant relapse-free survival (DRFS), and breast cancer-specific survival (BCSS) as well as a significant multivariate parameter for RFS, DRFS, and BCSS. In hormone receptor (HR)-positive/Her2-negative subtype cases, survivin mRNA expression was also an independent predictor in terms of DRFS. Immunohistochemically, positive staining was seen in the cytoplasm and/or nucleus of cancer cells, although this did not correlate with the mRNA level, and harbored no prognostic value.
High mRNA expression of survivin was an independent marker of poor prognosis both in the entire cohort and in the HR-positive/Her2-negative subtype, whereas the protein expression of survivin was not. These findings suggest that RT-qPCR can provide more reliable data than IHC in validating the prognostic significance of survivin for breast cancer patients.
生存素在乳腺癌的发生和发展中起关键作用。然而,其与乳腺癌患者预后的相关性长期以来一直存在争议。本研究的目的是在一系列人类乳腺癌病例中,从mRNA和蛋白质水平检测生存素的表达及其在预测临床结局中的作用。
采用定量实时逆转录聚合酶链反应(RT-qPCR)检测245例浸润性乳腺癌女性患者和13例导管原位癌患者的福尔马林固定石蜡包埋肿瘤组织中的生存素mRNA。此外,其中237例浸润性乳腺癌肿瘤可用于免疫组织化学(IHC)检测。评估生存素状态与临床病理特征及预后的关系。
RT-qPCR显示生存素mRNA高水平与高核分级、腋窝淋巴结阳性、激素受体状态阴性、Her2扩增阳性、Ki67标记指数较高以及血管侵犯的存在密切相关。在Cox比例回归模型分析中,生存素mRNA被证明是无复发生存(RFS)、远处无复发生存(DRFS)和乳腺癌特异性生存(BCSS)的显著单变量参数,也是RFS、DRFS和BCSS的显著多变量参数。在激素受体(HR)阳性/Her2阴性亚型病例中,生存素mRNA表达在DRFS方面也是一个独立的预测指标。免疫组织化学显示,癌细胞的细胞质和/或细胞核中可见阳性染色,尽管这与mRNA水平无关,且无预后价值。
生存素mRNA高表达是整个队列以及HR阳性/Her2阴性亚型中预后不良的独立标志物,而生存素的蛋白表达则不是。这些发现表明,在验证生存素对乳腺癌患者的预后意义方面,RT-qPCR比IHC能提供更可靠的数据。